CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Estrogen may cause the growth of ovarian cancer cells. Hormone therapy using tamoxifen may fight ovarian cancer by blocking the use of estrogen by the tumor cells. Measuring CA 125 levels may help doctors predict a patient's response to tamoxifen and help plan the best treatment.

PURPOSE: This phase II trial is studying CA 125 levels in treating patients with relapsed advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are receiving tamoxifen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mount Vernon Cancer Centre at Mount Vernon Hospital
• Treatments: Tamoxifen

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed advanced ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma

• Completed therapy for first relapse

• Had an elevated CA 125 level before starting relapse therapy with ≥ 50% fall by completion of that therapy or response according to RECIST criteria

• No significant cancer-related symptoms requiring urgent treatment

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Life expectancy > 3 months

• Hemoglobin > 10 g/dL

• WBC > 2,500/mm^3

• Platelet count > 100,000/mm^3

• Creatinine < 2 times upper limit of normal (ULN)

• AST/ALT < 2 times ULN

• Bilirubin < 1.5 times ULN

• No evidence of significant clinical disorder or laboratory finding that would preclude study participation

• No psychiatric disorder that would preclude informed consent

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• No other concurrent hormonal therapy, except hormone-replacement therapy

• Other concurrent medications allowed provided dose is stable